Volume 30, Issue 1 (Winter 2023)
Intern Med Today 2023, 30(1): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nayeri Ahangar E, Saadat P, Rahimi E, Doostdar A. Assessment of Cognitive Disorders and Depression in Patients with a History of COVID-19 in Babol, Iran, During 2022. Intern Med Today 2023; 30 (1)
URL: http://imtj.gmu.ac.ir/article-1-4101-en.html
URL: http://imtj.gmu.ac.ir/article-1-4101-en.html
1- General Practitioner, Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
2- Associate Professor of Neurology, Department of Psychiatry, Faculty of Medicine, Movement Disorder Research Center, Babol University of Medical Sciences, Babol, Iran
3- Master of Vital Statistics, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
4- Assistant Professor of Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran ,doostdar97@gmail.com
2- Associate Professor of Neurology, Department of Psychiatry, Faculty of Medicine, Movement Disorder Research Center, Babol University of Medical Sciences, Babol, Iran
3- Master of Vital Statistics, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
4- Assistant Professor of Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran ,
Abstract: (21 Views)
Aims COVID-19 threatens not only the physical health of individuals but also their mental health, particularly in terms of emotions and cognition. Understanding the neuropsychological sequelae of COVID-19 is essential for comprehensive knowledge of the disease and for developing appropriate treatment strategies for those infected. This study aimed to assess cognitive disorders and depression in patients with a history of COVID-19 in Babol, Iran, during 2022.
Materials & Methods This cross-sectional analytical study examined 270 patients with COVID-19, confirmed by a positive polymerase chain reaction test recorded at the Babol University of Medical Sciences Deputy of Health in 2022, who were randomly selected. The data collection tools included a demographic questionnaire, the Beck Depression Inventory-II (BDI-II), and the Montreal Cognitive Assessment (MoCA), which the patients completed. After collection, the data were analyzed using SPSS software (version 27), employing the Mann-Whitney U, Kruskal-Wallis, and Spearman's correlation tests at a significance level of less than 5%.
Findings The mean age of the patients was 49.40 ± 12.37 years, and 57% were female. The mean cognitive impairment score in patients was 26.28 ± 3.04, and the prevalence of cognitive impairment was 27.0%. Cognitive impairments showed a significant inverse correlation with age, duration of symptomatic illness, and education level (P < 0.05), and no significant relationship with patients' gender (P > 0.05). The mean depression score of the studied patients was 14.49 ± 7.71, which, according to the questionnaire's scoring method, indicated a mild level of depression in these patients. Patient depression had a significant direct statistical correlation with age, duration of symptomatic illness, and education level (P < 0.05) and no significant statistical relationship with the patients' gender (P > 0.05).
Conclusion Patients with COVID-19 had mild depressive symptoms and a 27% prevalence of cognitive impairment, while their mean cognitive impairment score remained within the normal range. Attention to the mental health of these patients is recommended to improve symptoms of depression and cognitive disorders.
Materials & Methods This cross-sectional analytical study examined 270 patients with COVID-19, confirmed by a positive polymerase chain reaction test recorded at the Babol University of Medical Sciences Deputy of Health in 2022, who were randomly selected. The data collection tools included a demographic questionnaire, the Beck Depression Inventory-II (BDI-II), and the Montreal Cognitive Assessment (MoCA), which the patients completed. After collection, the data were analyzed using SPSS software (version 27), employing the Mann-Whitney U, Kruskal-Wallis, and Spearman's correlation tests at a significance level of less than 5%.
Findings The mean age of the patients was 49.40 ± 12.37 years, and 57% were female. The mean cognitive impairment score in patients was 26.28 ± 3.04, and the prevalence of cognitive impairment was 27.0%. Cognitive impairments showed a significant inverse correlation with age, duration of symptomatic illness, and education level (P < 0.05), and no significant relationship with patients' gender (P > 0.05). The mean depression score of the studied patients was 14.49 ± 7.71, which, according to the questionnaire's scoring method, indicated a mild level of depression in these patients. Patient depression had a significant direct statistical correlation with age, duration of symptomatic illness, and education level (P < 0.05) and no significant statistical relationship with the patients' gender (P > 0.05).
Conclusion Patients with COVID-19 had mild depressive symptoms and a 27% prevalence of cognitive impairment, while their mean cognitive impairment score remained within the normal range. Attention to the mental health of these patients is recommended to improve symptoms of depression and cognitive disorders.
Type of Study: Original |
Subject:
Diseases
Received: 2025/08/23 | Accepted: 2025/11/14 | Published: 2023/12/7
Received: 2025/08/23 | Accepted: 2025/11/14 | Published: 2023/12/7
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |